How much funding has BlackThorn Therapeutics raised?

BlackThorn Therapeutics has raised $130.0M in total funding, most recently a series b round.

Who are BlackThorn Therapeutics's investors?

BlackThorn Therapeutics's investors include GV, ARCH Venture Partners, Polaris Partners, Premier Inc., Scripps Research, Vertex Ventures HC.

When was BlackThorn Therapeutics founded?

BlackThorn Therapeutics was founded in 2014.

Where is BlackThorn Therapeutics headquartered?

BlackThorn Therapeutics is headquartered in San Francisco, California, United States.

What industry is BlackThorn Therapeutics in?

BlackThorn Therapeutics operates in Biotech, Clinical Stage.

How many employees does BlackThorn Therapeutics have?

BlackThorn Therapeutics has 11-50 employees.

BlackThorn Therapeutics

Transforming lives with neurobehavioral therapies

San Francisco, United States · Founded 2014 · $130.0M raised

Biotech

Clinical Stage

Headquarters: San Francisco, California
Employees: 11–50
Founded: 2014
Business Model: B2B

Website: blackthornrx.com
Total Funding: $130.0M
Last Round: $76.0M Series BJun 2019
Rounds: 3

About

BlackThorn Therapeutics was a clinical-stage biopharmaceutical company dedicated to developing novel treatments for neurobehavioral disorders using its INFORM platform linking brain physiology to behavior. Founded in 2014 by Alex Tkachenko and Ed Roberts in San Francisco, the company raised $130M across four rounds including a $76M Series B. BlackThorn was later rebranded as Neumora Therapeutics, advancing its lead NOPR antagonist program into Phase 2 clinical trials.

Summary

BlackThorn Therapeutics is a Biotech company based in San Francisco, United States, founded in 2014. It has raised $130.0M in total across 3 rounds, most recently a $76.0M Series B round in Jun 2019. Investors include GV, ARCH Venture Partners and Polaris Partners.